Spero Total Stockholder Equity vs Total Liab Analysis

SPRO Stock

USD 1.63 0.02 1.24%

Spero Therapeutics financial indicator trend analysis is much more than just breaking down Spero Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spero Therapeutics is a good investment. Please check the relationship between Spero Therapeutics Total Stockholder Equity and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

Total Stockholder Equity vs Total Liab

Total Stockholder Equity vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spero Therapeutics Total Stockholder Equity account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Spero Therapeutics' Total Stockholder Equity and Total Liab is 0.58. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Total Liab in the same time period over historical financial statements of Spero Therapeutics, assuming nothing else is changed. The correlation between historical values of Spero Therapeutics' Total Stockholder Equity and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Spero Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Stockholder Equity i.e., Spero Therapeutics' Total Stockholder Equity and Total Liab go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Spero Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.At this time, Spero Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 4th of May 2024, Enterprise Value Multiple is likely to grow to 0.35, while Selling General Administrative is likely to drop about 21.3 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	106.2M	79.1M	76.6M	67.2M
Cost Of Revenue	1.1M	1.5M	367K	348.7K

Total Operating Expenses Cost Of Revenue

Spero Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.66	0.8	0.95	0.63	0.94	0.82	0.53	-0.86	-0.9	0.01	0.87	0.75	0.58	0.61	0.94	0.51	0.76	0.7	0.89	0.95	0.77	0.8	0.88	-0.74	0.99
Other Current Liab	0.66		0.63	0.64	0.37	0.65	0.87	0.15	-0.45	-0.61	0.29	0.48	0.5	0.77	0.68	0.71	0.21	0.44	0.43	0.76	0.66	0.52	0.6	0.77	-0.5	0.66
Total Current Liabilities	0.8	0.63		0.67	0.53	0.64	0.67	0.69	-0.57	-0.83	0.0	0.59	0.82	0.37	0.37	0.59	0.68	0.82	0.64	0.58	0.85	0.79	0.62	0.79	-0.57	0.73
Total Stockholder Equity	0.95	0.64	0.67		0.4	0.99	0.77	0.43	-0.79	-0.78	0.17	0.8	0.7	0.69	0.57	0.94	0.44	0.63	0.48	0.86	0.86	0.58	0.82	0.76	-0.73	0.95
Other Liab	0.63	0.37	0.53	0.4		0.39	0.52	0.47	-0.7	-0.75	-0.42	0.69	0.46	-0.03	0.43	0.58	0.41	0.7	0.98	0.61	0.68	0.9	0.37	0.71	-0.39	0.65
Net Tangible Assets	0.94	0.65	0.64	0.99	0.39		0.78	0.36	-0.8	-0.76	0.22	0.81	0.64	0.73	0.62	0.95	0.36	0.58	0.47	0.86	0.85	0.55	0.76	0.76	-0.82	0.95
Property Plant And Equipment Net	0.82	0.87	0.67	0.77	0.52	0.78		0.27	-0.68	-0.81	-0.09	0.72	0.6	0.77	0.84	0.83	0.28	0.61	0.59	0.82	0.86	0.65	0.62	0.94	-0.59	0.81
Current Deferred Revenue	0.53	0.15	0.69	0.43	0.47	0.36	0.27		-0.46	-0.7	-0.24	0.43	0.9	-0.16	-0.13	0.31	0.96	0.9	0.6	0.26	0.56	0.76	0.38	0.44	-0.36	0.46
Net Debt	-0.86	-0.45	-0.57	-0.79	-0.7	-0.8	-0.68	-0.46		0.87	0.2	-1.0	-0.56	-0.41	-0.62	-0.88	-0.37	-0.67	-0.73	-0.68	-0.84	-0.73	-0.73	-0.79	0.66	-0.89
Retained Earnings	-0.9	-0.61	-0.83	-0.78	-0.75	-0.76	-0.81	-0.7	0.87		0.28	-0.87	-0.8	-0.41	-0.61	-0.82	-0.61	-0.92	-0.83	-0.74	-0.96	-0.9	-0.69	-0.93	0.64	-0.89
Accounts Payable	0.01	0.29	0.0	0.17	-0.42	0.22	-0.09	-0.24	0.2	0.28		-0.21	-0.06	0.34	-0.18	0.08	-0.11	-0.32	-0.41	0.11	-0.19	-0.3	0.12	-0.25	-0.28	0.02
Cash	0.87	0.48	0.59	0.8	0.69	0.81	0.72	0.43	-1.0	-0.87	-0.21		0.54	0.45	0.67	0.88	0.33	0.65	0.73	0.7	0.86	0.72	0.73	0.82	-0.66	0.9
Non Current Assets Total	0.75	0.5	0.82	0.7	0.46	0.64	0.6	0.9	-0.56	-0.8	-0.06	0.54		0.23	0.14	0.57	0.93	0.91	0.61	0.55	0.73	0.79	0.55	0.66	-0.56	0.68
Non Currrent Assets Other	0.58	0.77	0.37	0.69	-0.03	0.73	0.77	-0.16	-0.41	-0.41	0.34	0.45	0.23		0.79	0.69	-0.15	0.13	0.01	0.63	0.56	0.09	0.54	0.6	-0.52	0.59
Other Assets	0.61	0.68	0.37	0.57	0.43	0.62	0.84	-0.13	-0.62	-0.61	-0.18	0.67	0.14	0.79		0.74	-0.21	0.29	0.42	0.68	0.71	0.37	0.47	0.8	-0.45	0.65
Cash And Short Term Investments	0.94	0.71	0.59	0.94	0.58	0.95	0.83	0.31	-0.88	-0.82	0.08	0.88	0.57	0.69	0.74		0.28	0.6	0.62	0.93	0.88	0.65	0.78	0.84	-0.74	0.97
Net Receivables	0.51	0.21	0.68	0.44	0.41	0.36	0.28	0.96	-0.37	-0.61	-0.11	0.33	0.93	-0.15	-0.21	0.28		0.84	0.55	0.28	0.49	0.72	0.35	0.4	-0.36	0.44
Common Stock Shares Outstanding	0.76	0.44	0.82	0.63	0.7	0.58	0.61	0.9	-0.67	-0.92	-0.32	0.65	0.91	0.13	0.29	0.6	0.84		0.81	0.58	0.83	0.92	0.51	0.76	-0.54	0.71
Non Current Liabilities Total	0.7	0.43	0.64	0.48	0.98	0.47	0.59	0.6	-0.73	-0.83	-0.41	0.73	0.61	0.01	0.42	0.62	0.55	0.81		0.64	0.75	0.96	0.43	0.77	-0.45	0.71
Other Current Assets	0.89	0.76	0.58	0.86	0.61	0.86	0.82	0.26	-0.68	-0.74	0.11	0.7	0.55	0.63	0.68	0.93	0.28	0.58	0.64		0.82	0.65	0.7	0.8	-0.62	0.91
Other Stockholder Equity	0.95	0.66	0.85	0.86	0.68	0.85	0.86	0.56	-0.84	-0.96	-0.19	0.86	0.73	0.56	0.71	0.88	0.49	0.83	0.75	0.82		0.82	0.72	0.95	-0.69	0.93
Total Liab	0.77	0.52	0.79	0.58	0.9	0.55	0.65	0.76	-0.73	-0.9	-0.3	0.72	0.79	0.09	0.37	0.65	0.72	0.92	0.96	0.65	0.82		0.51	0.81	-0.53	0.75
Deferred Long Term Liab	0.8	0.6	0.62	0.82	0.37	0.76	0.62	0.38	-0.73	-0.69	0.12	0.73	0.55	0.54	0.47	0.78	0.35	0.51	0.43	0.7	0.72	0.51		0.65	-0.33	0.8
Property Plant And Equipment Gross	0.88	0.77	0.79	0.76	0.71	0.76	0.94	0.44	-0.79	-0.93	-0.25	0.82	0.66	0.6	0.8	0.84	0.4	0.76	0.77	0.8	0.95	0.81	0.65		-0.61	0.87
Preferred Stock Total Equity	-0.74	-0.5	-0.57	-0.73	-0.39	-0.82	-0.59	-0.36	0.66	0.64	-0.28	-0.66	-0.56	-0.52	-0.45	-0.74	-0.36	-0.54	-0.45	-0.62	-0.69	-0.53	-0.33	-0.61		-0.74
Total Current Assets	0.99	0.66	0.73	0.95	0.65	0.95	0.81	0.46	-0.89	-0.89	0.02	0.9	0.68	0.59	0.65	0.97	0.44	0.71	0.71	0.91	0.93	0.75	0.8	0.87	-0.74

Click cells to compare fundamentals

Spero Therapeutics Account Relationship Matchups

Spero Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	106.1M	153.5M	171.1M	124.8M	182.4M	119.9M
Other Current Liab	21.6M	12.2M	14.4M	9.0M	6.9M	10.6M
Total Current Liabilities	26.7M	14.3M	18.7M	21.6M	37.2M	18.6M
Total Stockholder Equity	74.6M	132.0M	88.3M	75.9M	106.9M	84.2M
Other Liab	249K	177K	58.1M	22.3M	25.6M	26.9M
Net Tangible Assets	74.6M	132.0M	88.3M	75.9M	87.3M	70.9M
Property Plant And Equipment Net	7.1M	8.8M	7.6M	5.5M	4.2M	4.8M
Net Debt	(24.2M)	(77.4M)	(105.2M)	(102.5M)	(70.8M)	(74.3M)
Retained Earnings	(199.4M)	(277.7M)	(367.5M)	(413.9M)	(391.1M)	(371.5M)
Accounts Payable	4.1M	1.2M	1.1M	617K	1.4M	1.6M
Cash	29.7M	85.2M	112.6M	109.1M	76.3M	67.3M
Non Current Assets Total	24.1M	26.5M	13.2M	15.7M	51.2M	53.7M
Non Currrent Assets Other	16.9M	17.8M	5.6M	10.2M	435.0K	413.2K
Other Assets	3.5M	5.5M	5.6M	5.7M	1.0	0.95
Cash And Short Term Investments	82.0M	126.9M	146.4M	109.1M	76.3M	92.8M
Net Receivables	8.5M	6.2M	2.6M	1.1M	50.7M	53.2M
Common Stock Shares Outstanding	18.2M	22.4M	30.9M	37.6M	53.0M	55.6M
Liabilities And Stockholders Equity	106.1M	153.5M	171.1M	124.8M	182.4M	119.9M
Non Current Liabilities Total	4.9M	7.1M	64.1M	27.2M	38.3M	40.3M
Other Current Assets	4.8M	6.1M	8.8M	3.4M	4.2M	4.7M
Other Stockholder Equity	274.0M	409.7M	455.7M	489.8M	497.9M	302.9M
Total Liab	31.5M	21.4M	82.8M	48.9M	75.5M	79.3M
Property Plant And Equipment Gross	7.1M	8.8M	10.4M	8.7M	7.8M	6.0M
Total Current Assets	82.0M	126.9M	157.9M	109.1M	131.2M	101.2M
Accumulated Other Comprehensive Income	(28K)	16K	(7K)	(2K)	(2.3K)	(2.4K)
Short Term Debt	928K	947K	1.4M	1.7M	1.7M	1.1M
Property Plant Equipment	7.1M	1.7M	7.6M	5.5M	6.3M	3.9M
Common Stock	19K	29K	32K	52K	53K	50.4K
Inventory	(13.4M)	(12.2M)	(361K)	(4.5M)	1.0	1.05
Net Invested Capital	74.6M	132.0M	88.3M	75.9M	106.9M	106.5M
Net Working Capital	68.8M	124.8M	139.2M	91.9M	94.1M	112.3M

Currently Active Assets on Macroaxis

LAAC	Lithium Americas Corp
F	Ford Motor
CHPT	ChargePoint Holdings
AXL	American Axle Manufacturing
ICLN	iShares Global Clean

When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:

How To Invest In Spero

Details

Is Spero Stock a good investment?

Details

What is Spero Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Spero Stock analysis

When running Spero Therapeutics' price analysis, check to measure Spero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spero Therapeutics is operating at the current time. Most of Spero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spero Therapeutics' price. Additionally, you may evaluate how the addition of Spero Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account

Is Spero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.753

Earnings Share

0.43

Revenue Per Share

1.969

Quarterly Revenue Growth

0.55

Return On Assets

0.109

The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Spero Total Stockholder Equity vs Total Liab Analysis

Total Stockholder Equity vs Total Liab

Total Stockholder Equity vs Total Liab Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Total Liab

Spero Therapeutics fundamental ratios Correlations

Spero Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Spero Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Spero Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Non Current Liabilities Total	+ 0.98	Other Liab
Total Current Assets	+ 0.97	Cash And Short Term Investments
Net Receivables	+ 0.96	Current Deferred Revenue
Total Liab	+ 0.96	Non Current Liabilities Total

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Total Liab	- 0.9	Retained Earnings
Retained Earnings	- 0.9	Total Assets